CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10029|
|Strength||5mg, 10mg, 15mg and 25mg capsules|
|Funding Request||For the maintenance treatment of newly diagnosed multiple myeloma in patients after stem-cell transplantation|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|Submission Date||April 5, 2013|
|Submission Deemed Complete||April 19, 2013|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||April 19, 2013|
|Check-point meeting||August 6, 2013|
|pERC Meeting||September 19, 2013|
|Initial Recommendation Issued||October 3, 2013|
|Feedback Deadline ‡||October 18, 2013|
|Final Recommendation Issued||October 22, 2013|
|Notification to Implement Issued||November 6, 2013|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.